Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status

Tofacitinib is an oral, small-molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We summarize the efficacy and safety data of tofacitinib 5 or 10 mg twice daily in the UC clinical program, stratified by prior tumor necrosis factor inhibitor (TNFi) failure status.Efficacy w...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: William J. Sandborn, Laurent Peyrin–Biroulet, Ala I. Sharara, Chinyu Su, Irene Modesto, Rajiv Mundayat, Levent Mert Günay, Leonardo Salese, Bruce E. Sands
Médium: Artigo
Jazyk:angličtina
Vydáno: 2021
On-line přístup:https://doi.org/10.1016/j.cgh.2021.02.043
http://www.cghjournal.org/article/S1542356521002226/pdf
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1016/j.cgh.2021.02.043
http://www.cghjournal.org/article/S1542356521002226/pdf

Podobné jednotky